Biologic therapies: Charting the path from injectables to inhalation

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1693808&tp_key=60c9a6adc1

Event Overview:

Initially, nearly all biologic molecules are developed as injectable dosage forms. However, the lungs present an appealing route of administration for localised delivery as well as rapid systemic absorption. Biologic formulations can be tailored and refined for lung delivery, whether in liquid or dry powder format. This optimization process necessitates considerations of lung physiology, biologic drug stability, and interactions between the drug and the delivery device used.

Key Learning Objectives:

• Understand benefits for pulmonary administration of biologics: targeted delivery or rapid absorption.
• Learn characteristics for nebulization: particle size, stability, viscosity, device interactions, efficacy.
• Explore key properties for optimizing biologic dry powder formulations: stabilize molecule, ensure device compatibility, maximize therapy effectiveness.

Who Should Attend:

• R&D Directors, Heads or VPs
• Technical leads
• Biotech entrepreneurs
• Device engineers
• Formulation Scientists

Featured Speakers

Mireia Puig

Team Leader - Formulation and Process Innovation

Vectura

Joshua Newman

Senior Scientist - Pharmaceutical

Development

Vectura

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1693808&tp_key=60c9a6adc1